Compare AbCellera Biologics Inc (ABCL) vs Blackstone Inc (BX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Blackstone Inc — how do they compare? AbCellera Biologics Inc trades at $8.92 (market cap $2.85B), while Blackstone Inc trades at $146.53 (market cap $113.32B). The key difference: Blackstone Inc is far larger — about 39.8× AbCellera Biologics Inc's market cap, and Blackstone Inc pays a 3.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BX | |
|---|---|---|
Market Cap | $2.85B | $113.32B |
Sector | Health | Financials |
52-Week High | $9.76 | $188.68 |
52-Week Low | $2.78 | $102.12 |
Enterprise Value | $2.45B | — |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
